Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00431574
Status:
COMPLETED
Last Update Posted:
2024-02-07
First Post:
2007-02-02
Brief Title:
Antipsychotic Medication Extended Dosing Study
Sponsor:
Centre for Addiction and Mental Health
Organization:
Centre for Addiction and Mental Health
Study Overview
Official Title:
Antipsychotic Medication Extended Dosing Study
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In patients stabilized on their antipsychotic and demonstrating evidence of good clinical response there will not be a significant change in symptoms if their medication is decreased to every 2 days rather than daily This decrease in antipsychotic exposure will lead to a reduction in side effects as well as improved subjective response to treatment
Detailed Description:
The present study is a 6-month double-blind study of patients with schizophrenia stabilized on their current antipsychotic monotherapy for a period of at least 3 months After providing informed consent individuals will be randomly assigned to 1 of 2 treatment arms regular daily antipsychotic dosing or active medication at the same daily dose every 2nd day Various scales to measure clinical response and side effects will be administered at baseline as well as every 2 weeks thereafter Subjective scales will also be employed and lab evaluations will include plasma antipsychotic levels at baseline and endpoint as well as prolactin Our sample size will be 20group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None